Table 2 Results of univariate Cox regression analyses for the subject’s survival

Age ≥ 80 yrs

4.48^#

(3.65–5.49)

7.60^#

(5.80–9.95)

IADL < 24 pts

5.92^#

(4.77–7.35)

6.34^#

(4.86–8.27)

MNA < 12 pts

3.93^#

(3.21–4.82)

4.77^#

(3.68–6.18)

Negative inflammatory subgroup

Ref.

Ref.

Single-positive inflammatory subgroup

1.75^#

(1.34–2.29)

1.71^#

(1.28–2.29)

Double-positive inflammatory subgroup

3.98^#

(3.04–5.21)

4.17^#

(3.05–5.71)

Metabolic syndrome

0.88

(0.72–1.07)

1.12

(0.87–1.43)

Visceral obesity

0.59^#

(0.48–0.73)

0.49^#

(0.36–0.66)

Normal glucose control

Ref.

Ref.

Prediabetes

0.74*

(0.56–0.97)

1.10

(0.80–1.51)

Diabetes mellitus

1.29*

(1.04–1.60)

1.55^#

(1.19–2.04)

Hypertriglyceridemia

0.65^#

(0.51–0.84)

0.77

(0.59–1.02)

Hypercholesterolemia

0.60^#

(0.49–0.73)

0.45^#

(0.35–0.58)

Hypertension

0.99

(0.79–1.24)

1.21

(0.91–1.63)

Coronary artery disease

1.26*

(1.03–1.55)

1.84^#

(1.44–2.36)

Past stroke

2.07^#

(1.60–2.69)

2.06^#

(1.46–2.92)

Heart failure

1.47^#

(1.17–1.84)

3.05^#

(2.35–3.95)

Cancer survivors

1.45*

(1.08–1.95)

1.05

(0.71–1.57)

Use of statin

0.88

(0.72–1.08)

1.03

(0.81–1.32)

Albumin ≥ 40 g/L

0.29^#

(0.24–0.33)

0.26^#

(0.20–0.33)

eGFR < 45 ml/min/1.73m²

3.98^#

(3.01–5.25)

4.13^#

(3.11–5.47)